Former Miltenyi COO, Oliver Dick, joins Limula Strategic Advisory Board

Portrait of Oliver Dick.

• Oliver Dick joins Limula’s Strategic Advisory Board to support the commercial rollout of LimONE.
• He brings over 30 years of experience in life sciences, including roles at Miltenyi, QIAGEN, and Resolve Biosciences.
• His appointment strengthens Limula’s position as it prepares for broader adoption of its automated CGT platform.

Lausanne, Switzerland, June 18, 2025 – Limula, a Swiss life sciences tools company advancing automated solutions for cell and gene therapy (CGT) manufacturing today announced the appointment of Oliver Dick to its Strategic Advisory Board.

Dick brings over 30 years of leadership experience in the life sciences, pharmaceutical, and diagnostics sectors, including a pivotal role as Chief Operating Officer at Miltenyi Biotec, a leading player in CGT manufacturing. At Miltenyi, he was responsible for developing and executing the company’s global growth strategy across supply chain management, operations, process design, and manufacturing of instruments, reagents and consumables.

Prior to Miltenyi, Dick held senior positions including Vice President of Global Manufacturing for Life Sciences and Diagnostics at QIAGEN, where he spent more than a decade. He later served as COO at spatial biology innovator Resolve Biosciences and is now Chief Technology Officer at PL BioScience, while also leading the life sciences consultancy ODICON as CEO. He holds a PhD in chemical and bioprocess engineering from TU Dortmund University.

Dick’s deep industry expertise will play a key role as Limula prepares to bring its flagship product, LimONE, to market. With multiple end-users already working with fully functional prototypes, the company is now focused on refining its commercial strategy to support broader adoption.

“Having spent much of my career working to advance life science tools, I see in LimONE a truly differentiated solution,” said Dick. “I am excited to join Limula’s Strategic Advisory Board at this critical stage and look forward to supporting Luc and the team as they move toward the market.”

Limula CEO, Luc Henry, added: “Oliver’s appointment is perfectly timed, strengthening our position as we move toward commercial readiness. He brings deep industry expertise across product strategy, supply chain, and manufacturing, areas critical to our growth and the successful deployment of our LimONE platform.”

About Limula

Limula SA is a life science platform technology company based in Lausanne, Switzerland, dedicated to transforming the manufacturing of Cell & Gene Therapies. Their mission is to accelerate the development and commercialisation of new advanced therapies through an automated, on-demand, and scalable manufacturing solution. Limula’s proprietary platform integrates all functionalities into a single device, empowering therapeutics developers to bring life-saving treatments to patients more efficiently.

Contact Details

Luc Henry, DPhil
media@limula.ch
www.limula.ch